Cue Biopharma (CUE) Stock Price, News & Analysis

Company Overview

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $1.01 to $1.22
• 50-Day Range: $0.94 to $1.87
• 52-Week Range: $0.45 to $3.20
• Volume: 451,012 shs
• Average Volume: 453,450 shs
• Market Capitalization: $67.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Cue Biopharma Stock Analysis - MarketRank™

Cue Biopharma scored higher than 93% of companies evaluated by MarketBeat, and ranked 113th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cue Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cue Biopharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cue Biopharma are expected to grow in the coming year, from ($0.76) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cue Biopharma is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cue Biopharma is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cue Biopharma has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.58% of the outstanding shares of Cue Biopharma have been sold short.

Short Interest Ratio / Days to Cover

Cue Biopharma has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cue Biopharma has recently decreased by 6.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cue Biopharma does not currently pay a dividend.

Dividend Growth

Cue Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.58

Percentage of Shares Shorted

1.58% of the outstanding shares of Cue Biopharma have been sold short.

Short Interest Ratio / Days to Cover

Cue Biopharma has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cue Biopharma has recently decreased by 6.54%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.60

News Sentiment

Cue Biopharma has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cue Biopharma this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for CUE on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Cue Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $30,900.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

12.26% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 35.04% of the stock of Cue Biopharma is held by institutions.

CUE Stock Analysis - Frequently Asked Questions

How have CUE shares performed this year?

Cue Biopharma's stock was trading at $2.64 on January 1st, 2024. Since then, CUE shares have decreased by 59.5% and is now trading at $1.07.
View the best growth stocks for 2024 here.

How were Cue Biopharma's earnings last quarter?

Cue Biopharma, Inc. (NASDAQ:CUE) posted its earnings results on Wednesday, August, 14th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.09. The firm had revenue of $2.66 million for the quarter, compared to analysts' expectations of $1.12 million. Cue Biopharma had a negative net margin of 468.02% and a negative trailing twelve-month return on equity of 156.38%.

Who are Cue Biopharma's major shareholders?

Cue Biopharma's top institutional investors include Geode Capital Management LLC (1.05%), Sigma Planning Corp (0.83%), Good Life Advisors LLC (0.82%) and GSA Capital Partners LLP (0.60%). Insiders that own company stock include Aaron GL Fletcher, Daniel R Passeri, Anish Suri and Peter A Kiener.
View institutional ownership trends.

How do I buy shares of Cue Biopharma?

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cue Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 12/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CUE
• CUSIP: N/A
• CIK: 1645460
• Web: www.cuebiopharma.com
• Phone: (617) 949-2680
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +327.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-50,730,000.00
• Net Margins: -468.02%
• Pretax Margin: -468.02%
• Return on Equity: -156.38%
• Return on Assets: -88.07%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 2.22
• Quick Ratio: 2.22

Sales & Book Value

• Annual Sales: $9.53 million
• Price / Sales: 7.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.82 per share
• Price / Book: 1.43

Miscellaneous

• Outstanding Shares: 63,350,000
• Free Float: 55,583,000
• Market Cap: $74.10 million
• Optionable: Optionable
• Beta: 1.66